152 related articles for article (PubMed ID: 11394554)
1. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.
Mohr DC; Boudewyn AC; Likosky W; Levine E; Goodkin DE
Ann Behav Med; 2001; 23(2):125-32. PubMed ID: 11394554
[TBL] [Abstract][Full Text] [Related]
2. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.
Mohr DC; Cox D; Merluzzi N
Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392
[TBL] [Abstract][Full Text] [Related]
3. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
4. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
Limmroth V; Gerbershagen K
Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
[TBL] [Abstract][Full Text] [Related]
5. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
Turner AP; Williams RM; Sloan AP; Haselkorn JK
Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
[TBL] [Abstract][Full Text] [Related]
6. [A wide support of patients with multiple sclerosis promotes success of long-term therapy].
Sidorenko TV; Khachanova NV; Boĭko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():96-100. PubMed ID: 17172243
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
8. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications.
Mohr DC; Cox D; Epstein L; Boudewyn A
J Behav Ther Exp Psychiatry; 2002 Mar; 33(1):39-47. PubMed ID: 12389798
[TBL] [Abstract][Full Text] [Related]
9. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex).
Freedman SM; Cox D; Rosebrough T
J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302
[TBL] [Abstract][Full Text] [Related]
10. [The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy].
Popova EV; Novikova KV; Khachanova NV; Konovalova OE; Kozhieva MK; Davydovskaya MV; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10. Vyp. 2):48-52. PubMed ID: 29359733
[TBL] [Abstract][Full Text] [Related]
11. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program].
Visy JM; Gentin M; Bazerque C;
Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792
[TBL] [Abstract][Full Text] [Related]
12. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
13. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Devonshire VA; Feinstein A; Moriarty P
BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
[TBL] [Abstract][Full Text] [Related]
14. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
[TBL] [Abstract][Full Text] [Related]
16. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Devonshire VA; Verdun di Cantogno E
Ther Deliv; 2011 Nov; 2(11):1455-65. PubMed ID: 22844681
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
18. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Neilley LK; Griffin C; Stiebling B
Mult Scler; 1996 Dec; 2(5):222-6. PubMed ID: 9050360
[TBL] [Abstract][Full Text] [Related]
20. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
